{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-038499","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2026-05-27T20:30:22+00:00","discovered_at":"2026-05-27T20:32:00.370237+00:00","generated_at":"2026-05-27T20:38:07.487433+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Alnylam elects Benjamin F. Cravatt to board; shareholders re-elect directors and approve say-on-pay","bullets":["Benjamin F. Cravatt, Ph.D. elected to Board effective June 1, 2026, filling newly created eleventh seat; term expiring 2028 annual meeting.","Dr. Cravatt receives $75,000 annual cash retainer and initial stock option valued at $600,000 vesting over three years.","At May 20, 2026 annual meeting, shareholders re-elected Class I directors Arbuckle, Greenstreet, and Sigal with over 95% votes for each.","Say-on-pay approved with 111.8M for vs 8.6M against; PwC ratified as auditor with 119.8M votes for."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-038499","json":"https://secwatch.observer/filing/0001628280-26-038499.json","markdown":"https://secwatch.observer/filing/0001628280-26-038499.md","text":"https://secwatch.observer/filing/0001628280-26-038499.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/alny-20260520.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T20:38:07.487433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a7015ccdb8","claim":"Benjamin F. Cravatt was elected as Director at ALNYLAM PHARMACEUTICALS, INC..","evidence_excerpt":"Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0000927089-26-000101","ticker":"MGNO","company_name":"Magnolia Bancorp, Inc.","filed_at":"2026-06-01T18:15:36+00:00","headline":"Magnolia Bancorp names Robert Kimbro President/CEO; Hurley becomes Executive Chair","event_type":"leadership","sec_items":["5.02","5.07","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 5.07, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000927089-26-000101","json":"https://secwatch.observer/filing/0000927089-26-000101.json","markdown":"https://secwatch.observer/filing/0000927089-26-000101.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2033615/000092708926000101/0000927089-26-000101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2033615/000092708926000101/mban20260520_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm","comparable_excerpt":"On May 28, 2026, both the Company and the Association appointed Robert W. Kimbro as their President and Chief Executive Officer effective as of June 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2033615/000092708926000101/0000927089-26-000101-index.htm"}},{"accession":"0000860413-26-000048","ticker":"FIBK","company_name":"FIRST INTERSTATE BANCSYSTEM INC","filed_at":"2026-05-29T20:26:09+00:00","headline":"First Interstate BancSystem: three directors retire per age policy; charter amended to plurality voting","event_type":"leadership","sec_items":["5.02","5.03","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 5.07, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000860413-26-000048","json":"https://secwatch.observer/filing/0000860413-26-000048.json","markdown":"https://secwatch.observer/filing/0000860413-26-000048.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/860413/000086041326000048/0000860413-26-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/860413/000086041326000048/fibk-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm","comparable_excerpt":"on May 27, 2026, each of Ms. Patricia L. Moss and Messrs. David L. Jahnke and Stephen M. Lacy, each having reached the retirement age of 72, was deemed to have retired and resigned automatically from the Company’s Board of Directors","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/860413/000086041326000048/0000860413-26-000048-index.htm"}},{"accession":"0001437749-26-018719","ticker":"BELFA","company_name":"BEL FUSE INC /NJ","filed_at":"2026-05-28T18:24:48+00:00","headline":"Bel Fuse names Kenneth Lai as SVP ITDS; annual meeting approves 2026 equity plan","event_type":"leadership","sec_items":["5.02","5.07","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 5.07, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018719","json":"https://secwatch.observer/filing/0001437749-26-018719.json","markdown":"https://secwatch.observer/filing/0001437749-26-018719.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/729580/000143774926018719/0001437749-26-018719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/729580/000143774926018719/belfa20260526_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm","comparable_excerpt":"on May 22, 2026, the Company determined to name Kenneth Lai as Senior Vice President ITDS, effective late second quarter or early third quarter of 2026. In this role, Mr. Lai’s responsibilities expand to include the Company’s India and private label operations, in addition to China and other Asia locations. As a result of this change in responsibilities, Mr. Lai is no longer determined to be an “executive officer” or “officer” of the Company as defined in Rules 3b-7 and 16a-1(f) under the Securities Exchange Act of 1934, as amended, respectively.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/729580/000143774926018719/0001437749-26-018719-index.htm"}},{"accession":"0001140361-26-023584","ticker":"WTTR","company_name":"Select Water Solutions, Inc.","filed_at":"2026-06-01T21:00:50+00:00","headline":"Select Water Solutions COO Skarke moves to Chief Commercial Officer; no successor named","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023584","json":"https://secwatch.observer/filing/0001140361-26-023584.json","markdown":"https://secwatch.observer/filing/0001140361-26-023584.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/ef20075332_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm","comparable_excerpt":"Effective June 1, 2026, Michael C. Skarke transitioned from serving as the Executive Vice President and Chief Operating Officer of Select Water Solutions, Inc. (the “Company”) to serving as the Company’s Executive Vice President and Chief Commercial Officer,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm"}},{"accession":"0000060519-26-000024","ticker":"LPX","company_name":"LOUISIANA-PACIFIC CORP","filed_at":"2026-06-01T20:31:12+00:00","headline":"LP Building Solutions announces CFO succession: Alan Haughie to retire; Aaron Howald named CFO effective Sept 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000060519-26-000024","json":"https://secwatch.observer/filing/0000060519-26-000024.json","markdown":"https://secwatch.observer/filing/0000060519-26-000024.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/0000060519-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/lpx-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm","comparable_excerpt":"On May 27, 2026, Alan J.M. Haughie, Executive Vice President and Chief Financial Officer of Louisiana-Pacific Corporation (“LP”, the “Company”), notified the Board of Directors of LP (the “Board”) of his intention to retire from the role of Executive Vice President and Chief Financial Officer, effective September 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/0000060519-26-000024-index.htm"}},{"accession":"0002064307-26-000007","ticker":"LOGC","company_name":"ContextLogic Holdings Inc.","filed_at":"2026-06-01T20:15:17+00:00","headline":"ContextLogic appoints Scott Stewart as CFO & COO effective June 1; interim CFO resigns","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0002064307-26-000007","json":"https://secwatch.observer/filing/0002064307-26-000007.json","markdown":"https://secwatch.observer/filing/0002064307-26-000007.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/0002064307-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/logc-20260529.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm","comparable_excerpt":"On June 1, 2026 the Company also announced the appointment of Scott Stewart, age 53, as Chief Financial Officer and Chief Operating Officer, effective June 1, 2026 (the “Effective Date”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/0002064307-26-000007-index.htm"}},{"accession":"0001104659-26-068929","ticker":"VMI","company_name":"VALMONT INDUSTRIES INC","filed_at":"2026-06-01T20:15:13+00:00","headline":"Former CFO Thomas Liguori enters separation agreement; $4.9M retirement benefits","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.45,"calibrated_materiality_score":0.45,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068929","json":"https://secwatch.observer/filing/0001104659-26-068929.json","markdown":"https://secwatch.observer/filing/0001104659-26-068929.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/102729/000110465926068929/0001104659-26-068929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/102729/000110465926068929/vmi-20260526x8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm","comparable_excerpt":"Valmont Industries Inc. previously reported the appointment of John Schwietz as Valmont’s Executive Vice President and Chief Financial Officer and Corporate Secretary, effective April 8, 2026, to succeed Thomas Liguori.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/102729/000110465926068929/0001104659-26-068929-index.htm"}},{"accession":"0001213900-26-063506","ticker":"GPOR","company_name":"GULFPORT ENERGY CORP","filed_at":"2026-06-01T20:10:03+00:00","headline":"Gulfport Energy appoints Domenic Dell'Osso to Board; CEO role effective May 28, 2026","event_type":"leadership","sec_items":["5.02","5.07"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 5.07","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063506","json":"https://secwatch.observer/filing/0001213900-26-063506.json","markdown":"https://secwatch.observer/filing/0001213900-26-063506.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/874499/000121390026063506/0001213900-26-063506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874499/000121390026063506/ea0292798-8k_gulfport.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm","comparable_excerpt":"On May 28, 2026, the Board voted to increase the size of the Board to seven members and appointed Domenic J. Dell’Osso, Jr. to serve as a member of the Board until the 2027 Annual Meeting of Stockholders or until his successor is duly elected and qualified.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/874499/000121390026063506/0001213900-26-063506-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}